RenMice 기반 항체 개발 플랫폼

RenMab®

RenMab 마우스는 완전한 인간 항체 중쇄와 경쇄 가변 영역이 원위에서 대체되어 높은 다양성, 높은 친화성, 낮은 면역원성을 가진 완전 인간 단클론 항체 개발에 사용됩니다.

이 페이지에서

  • RenMab의 주요 특징
  • 검증 데이터
  • FAQs

포스터

모두 보기

    주요 특징

    1. 완전한 인간 중쇄 및 κ 경쇄 V(D)J 위치 대체
    Heavy Chain
    2. 완전한 인간 항체 라이브러리 다양성
    Fully human antibody img Fully human antibody img 2
    3. 야생형 마우스와 비슷한 강력한 면역 반응
    Immune response img Immune response img 2

    Frequently Asked Questions (FAQs) About RenMab

    1. What is RenMab®, and how does it generate fully human antibodies?

    RenMab® is Biocytogen’s fully human monoclonal antibody discovery platform within the RenMice® family. Powered by our proprietary Size-Unlimited and Precise Chromosome Engineering (SUPCE™) technology, RenMab® replaces mouse antibody genes with their human counterparts in situ. Natural heavy-light chain pairing and affinity maturation in vivo enable the discovery of diverse high-affinity fully human monoclonal antibodies with favorable developability.

    2. Why are fully human antibodies valuable for therapeutic development?

    Fully human antibodies can help reduce risk of immunogenicity associated with non-human sequences, including anti-drug antibody (ADA) formation. They also eliminate the need for downstream humanization, providing a direct route to therapeutic candidates while avoiding potential changes in binding or function during humanization.

    3. What is the genetic design strategy behind the RenMab® platform?

    Unlike random gene insertion approach, RenMab® uses precise in situ gene replacement to replace mouse heavy-chain V(D)J and kappa light-chain variable region loci with their human counterparts, creating a comprehensive human antibody variable-region repertoire. Our platform preserves native regulatory control to support B-cell development, natural antibody gene recombination and immune-driven antibody discovery.

    4. What other antibody discovery platforms and formats does Biocytogen offer?

    Beyond RenMab® for fully human monoclonal antibody discovery, Biocytogen offers: